Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07131592 · ClinicalTrials.gov registry record · Phase 4
Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery
A Phase 4 study of Breast Reductions and Drain Output After Breast Reduction Surgery, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT07131592: Recruiting Phase 4 study of Breast Reductions and Drain Output After Breast Reduction Surgery, sponsored by Massachusetts General Hospital.
NCT07131592 is a Phase 4 study of Breast Reductions and Drain Output After Breast Reduction Surgery that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 160 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07131592, a Phase 4 study of Breast Reductions and Drain Output After Breast Reduction Surgery, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to evaluate whether tranexamic acid (TXA), a medication that helps reduce bleeding, can decrease fluid drainage after breast reduction surgery. Participants will be randomly assigned to receive either intravenous TXA or no TXA during surgery. Additionally, one breast will receive TXA through the surgical drain, while the other will receive saline. This approach allows to compare the effects of TXA on fluid buildup and healing. The goal is to improve recovery and reduce complications after breast reduction surgery.
Primary Outcome
Drain outputs will be recorded separately for each breast twice daily until removal.
Conditions Studied
Interventions
- DRUG IV TXA
- DRUG Topical TXA
- DRUG Topical saline
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-11-18 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 4 |
What NCT07131592 shows while recruiting
NCT07131592 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Breast Reductions appearing as the primary indexed condition, and to 3 interventions - of which IV TXA is the first listed.
NCT07131592 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07131592 about?
NCT07131592 is a clinical study titled "Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery". This study aims to evaluate whether tranexamic acid (TXA), a medication that helps reduce bleeding, can decrease fluid drainage after breast reduction surgery. Participants will be randomly assigned to receive either intravenous TXA or no TXA during surgery. Additionally, one breast will receive TXA...
What is the current status of trial NCT07131592?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2025-11-18. Estimated completion is 2027-08-31.
What conditions does trial NCT07131592 study?
This clinical trial studies the following conditions: Breast Reductions, Drain Output After Breast Reduction Surgery.
What interventions are being tested in trial NCT07131592?
The interventions under investigation include: IV TXA (DRUG), Topical TXA (DRUG), Topical saline (DRUG).
Who is sponsoring clinical trial NCT07131592?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07131592 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Reductions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07131592's enrollment target sits among peer trials
160 507th of 2000 higher than 1,486 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI